Apatinib plus CDK4/6 inhibitor for first-line HR+/HER2- SNF4 breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, apatinib and a CDK4/6 inhibitor, as the first treatment for a specific type of advanced breast cancer that is HR+ and HER2-. It's designed for people with the 'SNF4' subtype, which is identified by a special analysis of your tumor sample.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of breast cancer called HR+/HER2-, which means it's fueled by hormones and not by a protein called HER2.
- Your breast cancer has been confirmed as the 'SNF4 subtype' through a special digital analysis of a biopsy sample.
- Your breast cancer is either advanced (can't be removed with surgery) or has spread to other parts of the body, and you haven't had any treatment for this advanced stage yet (except you may have taken a CDK4/6 inhibitor more than a year ago after initial treatment).
- You have at least one tumor that can be measured on a scan and hasn't been treated with radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests adding apatinib to a doctor-chosen standard treatment for advanced, hormone receptor-positive breast cancer that is HER2-negative. The goal is to see if this combination slows cancer growth in patients who have progressed after endocrine therapy and CDK4/6 inhibitors.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This Phase 2 trial studies whether combining fulvestrant with medicines that block DNA repair can help treat HR+/HER2- metastatic or inoperable breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor. It also aims to check the safety of this combination and see if it can control the cancer for longer.
This Phase 2 study tests whether apatinib combined with a CDK4/6 inhibitor and hormone therapy can better control advanced hormone receptor–positive, HER2-negative breast cancer. It may help shrink tumors or slow their growth, especially in cases that can’t be fully treated with surgery or radiation.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.